• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-1MEF filed by BioCardia Inc.

    8/29/24 8:09:56 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCDA alert in real time by email
    S-1MEF 1 bcda20240829_s1mef.htm FORM S-1MEF bcda20240829_s1mef.htm

     

    As filed with the Securities and Exchange Commission on August 29, 2024.

    Registration No. 333- 



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM S‑1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     


     

    BIOCARDIA, INC.

    (Exact name of Registrant as specified in its charter)

     


     

    Delaware

    2836

    23-2753988

    (State or other jurisdiction of

    incorporation or organization)

    (Primary Standard Industrial

    Classification Code Number)

    (I.R.S. Employer

    Identification Number)

     

    320 Soquel Way

    Sunnyvale, California 94085

    (650) 226-0120

    (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

     


     

    Peter Altman

    President and Chief Executive Officer

    320 Soquel Way

    Sunnyvale, California 94085

    (650) 226-0120

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     


     

    Copies to:

     

    Michael J. Danaher

    Austin D. March

    Wilson Sonsini Goodrich & Rosati,

    Professional Corporation

    650 Page Mill Road

    Palo Alto, CA 94304

    (650) 493-9300

    Ron Ben-Bassat

    Eric Victorson

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, NY 10020

    (212) 660-3000

     

    Approximate date of commencement of proposed sale to the public:

    As soon as practicable after this Registration Statement becomes effective.

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, or Securities Act, check the following box. ☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act.

     

    Large accelerated filer         

    ☐

    Accelerated filer          

    ☐

    Non-accelerated filer          

    ☒

    Smaller reporting company         

    ☒

       

    Emerging growth company         

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended. 

     



     

     

     

     

    EXPLANATORY NOTE AND INCORPORATION

    BY REFERENCE

     

    BioCardia, Inc. (the “Company”) is filing this registration statement with the Securities and Exchange Commission (the “SEC”) pursuant to Rule 462(b) under the Securities Act of 1933, as amended.

     

    This registration statement relates to the public offering of securities contemplated by the registration statement on Form S-1, as amended (File No. 333-281448) (the “Prior Registration Statement”) which was originally filed with the SEC on August 9, 2024 and declared effective on August 29, 2024.

     

    This registration statement covers the registration of an additional $1.2 million worth of Common Stock, or Pre-Funded Warrants, and accompanying Common Warrants, including an additional $1.2 million worth of shares of Common Stock underlying the Common Warrants, each as defined in the Prior Registration Statement.

     

    The information set forth in the Prior Registration Statement, including all exhibits thereto, is incorporated by reference in this filing.

     

    The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

     

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number

     

    Description

           

    5.1*

       

    Opinion of Wilson Sonsini Goodrich & Rosati, P.C.

           

    23.1*

       

    Consent of Independent Registered Public Accounting Firm.

           

    23.2*

       

    Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1).

           

    24.1†

       

    Power of Attorney (incorporated by reference to Exhibit 24.1 of Registration Statement on Form S-1 (Registration No. 333-281448))

           

    107*

       

    Filing Fee Table.

           
           

    *

       

    Filed herewith.

           
    †     Previously Filed.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sunnyvale, State of California, on August 29, 2024.

     

    BIOCARDIA, INC.

     
         

    By:

    /s/ Peter Altman, Ph.D.

     
     

    Peter Altman, Ph.D.

    President and Chief Executive Officer

     

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature

     

    Title

     

    Date

             

    /s/ Peter Altman, Ph.D.

     

    President and Chief Executive Officer and Director

     

    August 29, 2024

    Peter Altman, Ph.D.

     

    (Principal Executive Officer)

       
             

    /s/ David McClung

     

    Chief Financial Officer

     

    August 29, 2024

    David McClung

     

    (Principal Financial and Accounting Officer)

       
             

    *

     

    Director

     

    August 29, 2024

    Andrew Blank

           
             

    *

     

    Director

     

    August 29, 2024

    Jim Allen

           
             

    *

     

    Director

     

    August 29, 2024

    Bill Facteau

           
             

    *

     

    Director

     

    August 29, 2024

    Richard Krasno, Ph.D.

           
             

    *

     

    Director

     

    August 29, 2024

    Jay M. Moyes

           
             

    *

     

    Director

     

    August 29, 2024

    Simon Stertzer, M.D.

           

     

    *Pursuant to power of attorney

     

    By:   /s/ Peter Altman  

    Peter Altman, Ph.D.

    Attorney-in-fact 

     

     
    Get the next $BCDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCDA

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCDA
    SEC Filings

    View All

    BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    2/10/26 9:15:23 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    2/3/26 8:00:08 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by BioCardia Inc.

    S-8 - BioCardia, Inc. (0000925741) (Filer)

    12/18/25 5:13:25 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

    SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submission to FDA under its Q-Submission program for the approval of its Helix Transendocardial Delivery Catheter ("Helix") for intramyocardial therapeutic and diagnostic agent delivery.    The data supporting safety and effectiveness for the Helix Pre-Submission is from fifteen well-controlled clinical trials of cell and gene therapy delivery to the heart using Helix, where patients were enrolled in three primary cardiac clinical indications. The Helix

    2/10/26 9:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

    SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March 2-4 in Boston, Massachusetts. On behalf of the CardiAMP HF investigators, the presentation will be made by Dr. Amish Raval, M.D., Professor of Medicine at UW School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal

    2/3/26 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

    SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on our CardiAMP Cell Therapy intended for treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). The meeting was held in further preparation for formal clinical consultation on acceptability of the existing clinical data for submission of an application for approval. Based on the discussions in the most recent meeting, PMDA said it will allow BioCardia to

    12/16/25 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on BioCardia with a new price target

    HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00

    12/20/21 6:05:04 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia downgraded by Dawson James

    Dawson James downgraded BioCardia from Buy to Neutral

    4/16/21 7:22:02 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Leadership Updates

    Live Leadership Updates

    View All

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

    SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir

    11/24/25 8:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Financials

    Live finance-specific insights

    View All

    BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2025 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. "This quarter's $6 million financing is actively supporting approvability discussions of CardiAMP

    11/12/25 4:40:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

    SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2025 by conference call on Wednesday, November 12, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10204565/1005a9b26d8. Please note that registered participants will receive their dial-in number upon registration. F

    11/5/25 7:29:23 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2025 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic hear

    8/11/25 9:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioCardia Inc.

    SC 13G - BioCardia, Inc. (0000925741) (Subject)

    9/6/24 7:45:48 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

    SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

    4/5/24 4:13:08 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

    SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

    2/27/24 4:53:40 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care